Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$4.53 +10.0%	$4.17	$3.35 ▼ $22.00	$106.59M	0.52	85,423 shs	135,129 shs
MREO Mereo BioPharma Group	$2.72 -0.7%	$2.48	$1.58 ▼ $5.02	$435.66M	0.47	1.10 million shs	2.01 million shs
ORIC Oric Pharmaceuticals	$10.49 +4.9%	$6.82	$3.90 ▼ $14.67	$852.24M	1.49	787,784 shs	1.16 million shs
TRML Tourmaline Bio	$16.94 -0.5%	$16.83	$11.56 ▼ $29.79	$437.17M	2.04	272,407 shs	176,622 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	+9.95%	+15.27%	+26.89%	-37.77%	-76.39%
MREO Mereo BioPharma Group	-0.73%	-2.86%	+21.43%	+14.77%	-27.66%
ORIC Oric Pharmaceuticals	+4.90%	+16.17%	+65.20%	+79.32%	+46.71%
TRML Tourmaline Bio	-0.47%	-6.82%	+10.57%	+0.59%	+15.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	2.7915 of 5 stars	3.6	3.0	0.0	2.0	0.8	1.3
MREO Mereo BioPharma Group	1.2212 of 5 stars	3.6	1.0	0.0	0.0	1.7	0.0
ORIC Oric Pharmaceuticals	4.1824 of 5 stars	3.5	0.0	4.3	3.4	3.3	0.6
TRML Tourmaline Bio	2.7986 of 5 stars	3.5	3.0	0.0	3.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.17	Buy	$22.50	396.69% Upside
MREO Mereo BioPharma Group	3.20	Buy	$7.60	179.41% Upside
ORIC Oric Pharmaceuticals	3.00	Buy	$19.17	82.71% Upside
TRML Tourmaline Bio	3.00	Buy	$49.33	191.22% Upside

Current Analyst Ratings Breakdown

Latest CTNM, TRML, MREO, and ORIC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/29/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00
5/15/2025	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/6/2025	ORIC Oric Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $12.00
5/6/2025	ORIC Oric Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/5/2025	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
5/5/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/5/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	2.34	N/A	N/A	$7.66 per share	0.59
MREO Mereo BioPharma Group	$10M	43.25	N/A	N/A	$0.39 per share	6.97
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$11.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)
ORIC Oric Pharmaceuticals	-$127.85M	-$1.87	N/A	N/A	N/A	N/A	-51.14%	-46.29%	8/11/2025 (Estimated)
TRML Tourmaline Bio	-$73.21M	-$3.21	N/A	N/A	N/A	N/A	-26.75%	-26.11%	8/6/2025 (Estimated)

Latest CTNM, TRML, MREO, and ORIC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/5/2025	Q1 2025	ORIC Oric Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	21.47	21.47
MREO Mereo BioPharma Group	N/A	8.92	8.92
ORIC Oric Pharmaceuticals	N/A	12.00	12.00
TRML Tourmaline Bio	N/A	33.87	33.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
MREO Mereo BioPharma Group	62.83%
ORIC Oric Pharmaceuticals	95.05%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
MREO Mereo BioPharma Group	5.50%
ORIC Oric Pharmaceuticals	5.55%
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
ORIC Oric Pharmaceuticals	80	85.22 million	80.49 million	Optionable
TRML Tourmaline Bio	44	25.68 million	22.35 million	Optionable

CTNM, TRML, MREO, and ORIC Headlines

Recent News About These Companies

TRML - Tourmaline Bio Inc Executives - Morningstar

June 24 at 5:50 PM | morningstar.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from Brokerages

June 24 at 2:41 AM | marketbeat.com

Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings

June 11, 2025 | marketbeat.com

Two Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)

June 10, 2025 | marketbeat.com

Tourmaline Bio Elects Directors and Ratifies Auditor

June 6, 2025 | tipranks.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DE

June 6, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Trading Up 7.2% - Here's What Happened

June 5, 2025 | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of "Buy" from Brokerages

May 31, 2025 | marketbeat.com

H.C. Wainwright maintains $50 target on Tourmaline Bio stock

May 29, 2025 | uk.investing.com

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

May 29, 2025 | msn.com

Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

May 28, 2025 | marketbeat.com

Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings

May 27, 2025 | marketbeat.com

29,844 Shares in Tourmaline Bio, Inc. (NASDAQ:TRML) Purchased by Rafferty Asset Management LLC

May 25, 2025 | marketbeat.com

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)

May 23, 2025 | msn.com

Tourmaline shares waver as investors mull mid-stage pacibekitug data

May 21, 2025 | thepharmaletter.com

Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win

May 21, 2025 | fiercebiotech.com

Tourmaline Bio posts mid-stage data for anti-inflammatory agent

May 21, 2025 | msn.com

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 20, 2025 | seekingalpha.com

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

May 19, 2025 | globenewswire.com

Tourmaline Bio Reports Q1 2025 Financial Results

May 7, 2025 | tipranks.com

Why Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%

May 3, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, TRML, MREO, and ORIC Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$4.53 +0.41 (+9.95%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$4.50 -0.03 (-0.66%)

As of 04:05 AM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Mereo BioPharma Group NASDAQ:MREO

$2.72 -0.02 (-0.73%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$2.74 +0.02 (+0.92%)

As of 06/24/2025 07:21 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Oric Pharmaceuticals NASDAQ:ORIC

$10.49 +0.49 (+4.90%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$10.34 -0.15 (-1.43%)

As of 06/24/2025 07:58 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Tourmaline Bio NASDAQ:TRML

$16.94 -0.08 (-0.47%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$16.95 +0.01 (+0.08%)

As of 04:05 AM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time